OncoSil Medical (ASX:OSL) started its commercial rollout in Germany with the first treatment using the OncoSil device at Universitatsklinikum Augsburg on Wednesday, according to a Thursday filing with the Australian bourse.
The firm said it would collaborate with German physicians, healthcare institutions, and health insurers to support the adoption of the device, developed for the treatment of unresectable locally advanced pancreatic cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.